708273-57-8

Basic information

• Product Name: 4-Hydroxy-4-(6-methoxypyridin-3-yl)cyclohexanone
• Synonyms: 4-Hydroxy-4-(6-methoxypyridin-3-yl)cyclohexanone;4-Hydroxy-4-(6-Methoxy-3-pyridinyl)cyclohexanone
• CAS NO: 708273-57-8
• Molecular Formula: C₁₂H₁₅NO₃
• Molecular Weight: 221.25
• Mol File: 708273-57-8.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 389.6 °C at 760 mmHg
• Flash Point: 189.4 °C
• Appearance: /
• Density: 1.230
• Refractive Index: 1.564
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-Hydroxy-4-(6-methoxypyridin-3-yl)cyclohexanone(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Hydroxy-4-(6-methoxypyridin-3-yl)cyclohexanone(708273-57-8)
• EPA Substance Registry System: 4-Hydroxy-4-(6-methoxypyridin-3-yl)cyclohexanone(708273-57-8)

Safety Data

• Hazardous Substances Data: 708273-57-8(Hazardous Substances Data)

Usage

General Description

4-Hydroxy-4-(6-methoxypyridin-3-yl)cyclohexanone is a chemical compound with the molecular formula C12H15NO3. It is a derivative of cyclohexanone and contains a hydroxy group and a methoxy-substituted pyridine ring. 4-Hydroxy-4-(6-methoxypyridin-3-yl)cyclohexanone is commonly used in the pharmaceutical industry for its potential medicinal properties and is under research for its anti-inflammatory and antioxidant effects. It has also been studied for its potential application in the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's. Its structure and properties make it a valuable target for further investigation in drug development and therapeutic applications.

InChI:InChI=1/C12H15NO3/c1-16-11-3-2-9(8-13-11)12(15)6-4-10(14)5-7-12/h2-3,8,15H,4-7H2,1H3

Upstream product

• 4746-97-8 cyclohexanedione monoethylene ketal 
• 13472-85-0 2-methoxy-5-bromopyridine 
• 708273-56-7 8-(6-methoxy-pyridin-3-yl)-1,4-dioxa-spiro[4.5]decan-8-ol 

Downstream Products

• 1401993-39-2 8-[4-hydroxy-4-(6-methoxypyridin-3-yl)cyclohexyl]-3-methyl-4-{[7-(trifluoromethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1-oxa-8-azaspiro[4.5]dec-3-en-2-one 
• 887401-93-6 N-(2-((R)-1-(trans-4-hydroxy-4-(6-methoxypyridin-3-yl)cyclohexyl)pyrrolidin-3-ylamino)-2-oxoethyl)-3-(trifluoromethyl)benzamide bismethanesulfonate 
• 887401-92-5 INCB₃₂₈₄ 
• 1161428-49-4 (1-(4-hydroxy-4-(6-methoxypyridin-3-yl)cyclohexyl)-3-(methoxymethyl)pyrrolidin-3-yl)(3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)methanone 
• 1252689-15-8 4-(6-Methoxy-pyridin-3-yl)-cyclohex-3-enone 

Relevant articles and documents

CHEMOKING RECEPTOR ANTAGONISTS

Disclosed herein are chemokine receptor antagonists of formula (I) wherein G1, X1, X2, and X3 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.

Discovery of INCB3284, a potent, selective, and orally bioavailable hCCR2 antagonist

We report the identification of 13 (INCB3284) as a potent human CCR2 (hCCR2) antagonist. INCB3284 exhibited an IC50 of 3.7 nM in antagonism of monocyte chemoattractant protein-1 binding to hCCR2, an IC 50 of 4.7 nM in antagonism of c

4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2

The present invention comprises compounds of Formula (I). wherein: R1, R2, R3, and R4 are as defined in the specification. The invention also comprises pharmaceutical compositions comprising the compounds of formula (I) and methods of preventing, treating or ameliorating a CCR2 mediated syndrome, disorder or disease, for example, type II diabetes, obesity or asthma, by administering the compounds of formula (I).